论文部分内容阅读
目的观察灯盏花素对重症急性胰腺炎(severe acute pancreatitis,SAP)的治疗作用。方法将62例SAP患者随机分为对照组(30例)和治疗组(32例),对照组采用常规治疗,治疗组在常规治疗的基础上加用灯盏花素。观察两组患者治疗前与治疗第4、10天血肌酐(Cr)、尿素氮(BUN)、24 h尿蛋白水平、血浆TNF-α、IL-6、IL-8水平、APACHEⅡ评分变化,比较两组患者急性肾功能衰竭(acute renal failure,ARF)发生率、病死率。结果经灯盏花素治疗后,患者ARF发生率、病死率均明显下降。治疗组血Cr水平在治疗第4、10天均显著低于对照组(P<0.05),血BUN、24 h尿蛋白含量水平在治疗第4天显著低于对照组(P<0.05)。治疗第4天治疗组与对照组血浆TNF-α、IL-6、IL-8水平、APACHEⅡ评分差异均无显著性(P>0.05);治疗第10天治疗组血浆TNF-α、IL-6、IL-8水平及APACHEⅡ评分均显著低于对照组(P<0.05)。结论灯盏花素可以改善SAP患者肾功能,降低血浆炎性细胞因子水平,从而起到治疗作用。
Objective To observe the therapeutic effect of Breviscapine on severe acute pancreatitis (SAP). Methods Sixty-two patients with SAP were randomly divided into control group (n = 30) and treatment group (n = 32). The control group was treated with conventional therapy. The treatment group was given breviscapine on the basis of routine treatment. The changes of serum creatinine (Cr), blood urea nitrogen (BUN), 24 h urinary protein level, plasma TNF-α, IL-6 and IL-8 levels and APACHEⅡ scores before treatment and 4 and 10 days after treatment were observed in both groups Two groups of patients with acute renal failure (ARF) incidence, mortality. Results Breviscapine treatment, the incidence of ARF patients, mortality were significantly decreased. Blood Cr levels in the treatment group were significantly lower than those in the control group on the 4th and 10th days (P <0.05), while levels of BUN and 24-hour urine protein in the treatment group were significantly lower than those of the control group on the 4th day after treatment (P <0.05). There was no significant difference in plasma TNF-α, IL-6 and IL-8 levels and APACHEⅡ scores between the treatment group and the control group on the 4th day of treatment (P> 0.05) , IL-8 levels and APACHE Ⅱ scores were significantly lower than the control group (P <0.05). Conclusion Breviscapine can improve renal function in patients with SAP and lower plasma levels of inflammatory cytokines, which play a therapeutic role.